Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Camidge on Targeted Therapies in Adjuvant NSCLC

May 7th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the selective administration of targeted therapies in the adjuvant setting for patients with non-small cell lung cancer.

Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership

May 7th 2013

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.

AACR President Frank McCormick, PhD, Reflects on Past Progress and Looks to the Future

May 6th 2013

An interesting conversation with this year's AACR president, Frank McCormick, PhD, on the next big area of interest in cancer research, and what the future holds for cancer research progress.

Dr. Tripathy Reviews Targeted Therapies in Breast Cancer

May 3rd 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Serendipity in Science: NSCLC Specialist Matches Therapies With Targets

May 3rd 2013

An interview with Alice Tsang Shaw, MD, PhD, who has won broad recognition for her contributions to the treatment of NSCLC, including the use of crizotinib to target the ROS1 gene rearrangement and research into other emerging agents.

Dr. Carey on the Future of Clinical Trial Design

May 2nd 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.

Worldwide Effort Yields Major Advances in Identifying Genetic Risks for Breast, Prostate, and Ovarian Cancer

April 30th 2013

A large, international study has yielded a wealth of new information about genetic alterations that can increase an individual's risk of breast, prostate, and ovarian cancer.

Wide Variation Found in EGFR Testing Patterns

April 29th 2013

A study of patients newly initiated to erlotinib therapy for NSCLC found that there is no uniformity in the billing codes used for pharmacogenomic testing prior to starting the drug, making it difficult to analyze treatment patterns and cost impact.

USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical Practice

April 29th 2013

Barbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.

Dutch Researcher Focuses on Fc Signaling in Targeting CD20

April 25th 2013

Jeanette H.W. Leusen, PhD, focuses on studying the working mechanisms of therapeutic antibodies and the biology of fragment crystallizable receptors, including the anti-CD20 monoclonal antibody rituximab in patients with non-Hodgkin lymphoma.

Targeting CD20: Rituximab's Success Fuels Interest in New Agents

April 25th 2013

A large proportion of patients become rituximab-refractory, which has prompted the development of newer CD20 agents with altered structures that are designed to improve upon rituximab's performance.

Dr. Caudle on Upcoming Breast Cancer Trial Results

April 24th 2013

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Dr. Andre Discusses Testing for Genomic Alterations

April 22nd 2013

Fabrice Andre, MD, PhD, from the Institut Gustave Roussy, Villejuif, France, gives an overview of methods for improving the effectiveness of genomic alteration testing in clinical trials that explore novel targeted agents in breast cancer.

Intraperitoneal Chemotherapy Improves Survival in Ovarian Cancer Patients With Low BRCA1 Levels

April 19th 2013

Patients with epithelial ovarian cancer (EOC) and low levels of the BRCA1 protein had significantly improved overall survival (OS) when their platinum-based chemotherapy was delivered abdominally by injection

April 2013 Biotech Focus: Tracking the Oncology Pipeline

April 19th 2013

The Biotech Focus series provides updates on advances in the oncology treatment pipeline. In each entry, summaries of ongoing research, breaking news, and FDA decisions relating to a variety of cancers are presented.

US Supreme Court Hears Arguments in BRCA1/2 Patenting Case

April 18th 2013

The question of whether it should be legal to patent genes has reached the US Supreme Court, and the impending decision by the highest federal court in the country could significantly transform the current research landscape.

Use of Personalized Medicine to Select Adjuvant Breast Cancer Therapy

April 17th 2013

Clinical trials are under way that may change the way risk of recurrence is assessed for early-stage breast cancer patients, allowing for individualization of therapy.

Emanuel Petricoin Describes Screening With Biomarkers

April 16th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

Embracing a Challenge: Breast Cancer Expert Pushes Forward After Much Success

April 12th 2013

An interview with JosÃ© Baselga, MD, PhD, who helped to develop new drugs and combination therapies for the treatment of breast cancer, including the early targeted therapy trastuzumab and the more recent pertuzumab.

Robust Oncology Pipeline Described

April 11th 2013

Oncology continues to lead all therapeutic areas in drug development research, with nearly 5500 of more than 17,000 projects in the works.